Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Denecimig · 1 trial · 1 indication
Measured as count of treated bleeds.
| Arm | Type | Description |
|---|---|---|
| Denecimig | EXPERIMENTAL | Denecimig will be administered subcutaneously. |
| Name | Type | Description |
|---|---|---|
| Denecimig | DRUG | Participants will receive subcutaneous (s.c.) injections of denecimig. |
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male or female participants (sex assigned at birth, inclusive of...
Denecimig is an investigational small molecule being developed by Novo Nordisk A/S for the treatment of haemophilia A. It is currently in Phase 3 clinical development and has not been approved for commercial use. The program includes a study in adults with acquired haemophilia A.
Denecimig is being studied for the treatment of haemophilia A, including acquired haemophilia A in adults. The ongoing Phase 3 trial enrolls adults aged 18 years and older with acquired haemophilia A. As an investigational therapy, Denecimig has not been approved for any indication.
Denecimig is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 3 clinical program evaluating Denecimig in adults with acquired haemophilia A.
Denecimig is in Phase 3 clinical development. One Phase 3 trial is registered and is currently active, with a status of not yet recruiting. Denecimig remains investigational and has not received regulatory approval for haemophilia A or any other indication.
Denecimig is being evaluated in the Phase 3 trial NCT07830732, titled A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A. The study plans to enroll 84 adults aged 18 years and older across sites in the United States, Europe, Asia, Latin America, Australia, and South Africa.
Yes, Denecimig is also known as Mim8. The Phase 3 study NCT07830732 refers to the agent as Denecimig (Mim8), confirming that both names describe the same investigational compound being developed by Novo Nordisk A/S for acquired haemophilia A.